Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3337858
Max Phase: Preclinical
Molecular Formula: C39H44I2N4O2
Molecular Weight: 600.81
Molecule Type: Small molecule
Associated Items:
ID: ALA3337858
Max Phase: Preclinical
Molecular Formula: C39H44I2N4O2
Molecular Weight: 600.81
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[N+]12CC[C@@]34c5ccccc5N5[C@@H]6OC=C7C[N+]8(C)CC[C@]9%10c%11ccccc%11N([C@@H]%11OCC=C(C1)[C@H](C[C@@H]32)[C@@H]%11[C@H]54)[C@H]9[C@H]6[C@H]7C[C@@H]%108.[I-].[I-]
Standard InChI: InChI=1S/C39H44N4O2.2HI/c1-42-14-12-38-27-8-4-6-10-29(27)41-34(38)32-24(17-30(38)42)22(19-42)11-16-44-36(32)40-28-9-5-3-7-26(28)39-13-15-43(2)20-23-21-45-37(41)33(35(39)40)25(23)18-31(39)43;;/h3-11,21,24-25,30-37H,12-20H2,1-2H3;2*1H/q+2;;/p-2/t24-,25-,30-,31-,32+,33+,34-,35-,36+,37+,38+,39+,42?,43?;;/m0../s1
Standard InChI Key: SIEVQGMWOMEGBR-IVTOCARJSA-L
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 600.81 | Molecular Weight (Monoisotopic): 600.3453 | AlogP: 4.51 | #Rotatable Bonds: 0 |
Polar Surface Area: 24.94 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: -4.16 | CX LogD: -4.16 |
Aromatic Rings: 2 | Heavy Atoms: 45 | QED Weighted: 0.33 | Np Likeness Score: 1.80 |
1. Zlotos DP, Tränkle C, Holzgrabe U, Gündisch D, Jensen AA.. (2014) Semisynthetic analogues of toxiferine I and their pharmacological properties at α7 nAChRs, muscle-type nAChRs, and the allosteric binding site of muscarinic M2 receptors., 77 (9): [PMID:25192059] [10.1021/np500259j] |
Source(1):